宫颈癌

Marth C, Landoni F, Mahner S, et al. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(suppl_4):iv72-83. 摘要

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: cervical cancer [internet publication].全文

Bhatla N, Aoki D, Sharma DN, et al. Cancer of the cervix uteri: 2021 update. Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(suppl 1):28-44.全文  摘要

Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society CA Cancer J Clin. 2020 Sep;70(5):321-46.全文  摘要

1. WHO Classification of Tumors Editorial Board. Female genital tumors. In: World Health Organization. Classification of tumors. 5th ed (vol. 4). World Health Organization, IARC Press; 5th ed (vol. 4). 2020.

2. World Health Organization. Human papillomavirus (HPV) and cervical cancer: fact sheet. Aug 2023 [internet publication].全文

3. European Commission: European Cancer Information System​. Cervical cancer burden in EU-27. 2021 [internet publication].全文

4. National Cancer Institute: Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: cervical cancer. 2023 [internet publication].全文

5. Louie KS, de Sanjose S, Diaz M, et al. Early age at first sexual intercourse and early pregnancy are risk factors for cervical cancer in developing countries. Br J Cancer. 2009 Apr 7;100(7):1191-7.全文  摘要

6. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma and sexual behavior: collaborative reanalysis of individual data on 15,461 women with cervical carcinoma and 29,164 women without cervical carcinoma from 21 epidemiological studies. Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1060-9.全文  摘要

7. Appleby P, Beral V, Berrington de González A, et al. Carcinoma of the cervix and tobacco smoking: Collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer. 2006 Mar 15;118(6):1481-95. 摘要

8. Liu G, Sharma M, Tan N, et al. HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer. AIDS. 2018 Mar 27;32(6):795-808.全文  摘要

9. Hessol NA, Whittemore H, Vittinghoff E, et al. Incidence of first and second primary cancers diagnosed among people with HIV, 1985-2013: a population-based, registry linkage study. Lancet HIV. 2018 Nov;5(11):e647-55. 摘要

10. Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007 Jul 7;370(9581):59-67. 摘要

11. Parikh S, Brennan P, Boffetta P. Meta-analysis of social inequality and the risk of cervical cancer. Int J Cancer. 2003 Jul 10;105(5):687-91.全文  摘要

12. González CA, Travier N, Luján-Barroso L, et al. Dietary factors and in situ and invasive cervical cancer risk in the European prospective investigation into cancer and nutrition study. Int J Cancer. 2011 Jul 19;129(2):449-59.全文  摘要

13. International Collaboration of Epidemiological Studies of Cervical Cancer., Appleby P, Beral V, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007 Nov 10;370(9599):1609-21. 摘要

14. Landy R, Pesola F, Castañón A, et al. Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case-control study. Br J Cancer. 2016 Oct 25;115(9):1140-6.全文  摘要

15. Vesco KK, Whitlock EP, Eder M, et al. Screening for cervical cancer: a systematic evidence review for the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality (US); 2011 May.全文  摘要

16. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999 Sep;189(1):12-9. 摘要

17. Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003 Feb 6;348(6):518-27.全文  摘要

18. Castellsague X, Diaz M, de Sanjose S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006 Mar 1;98(5):303-15. 摘要

19. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998 Feb 12;338(7):423-8.全文  摘要

20. Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis. 1999 Nov;180(5):1415-23.全文  摘要

21. Centers for Disease Control and Prevention. Manual for the surveillance of vaccine-preventable diseases. Chapter 5: Human papillomavirus. 28 Apr 2020 [internet publication].全文

22. Mayrand MH, Duarte-Franco E, Rodrigues I, et al; Canadian Cervical Cancer Screening Trial Study Group. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007 Oct 18;357(16):1579-88.全文  摘要

23. Watson RA. Human papillomavirus: confronting the epidemic – a urologist's perspective. Rev Urol. 2005 Summer;7(3):135-44.全文  摘要

24. Schwarz E, Freese UK, Gissmann L, et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature. 1985 Mar 7-13;314(6006):111-4. 摘要

25. Yim EK, Park JS. The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis. Cancer Res Treat. 2005 Dec;37(6):319-24.全文  摘要

26. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008 May;9(5):425-34. 摘要

27. Ferenczy A, Franco E. Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncol. 2002 Jan;3(1):11-6. 摘要

28. Rositch AF, Nowak RG, Gravitt PE. Increased age and race-specific incidence of cervical cancer after correction for hysterectomy prevalence in the United States from 2000 to 2009. Cancer. 2014 Jul 1;120(13):2032-8.全文  摘要

29. Feldman S, Cook E, Davis M, et al. Cervical cancer incidence among elderly women in Massachusetts compared with younger women. J Low Genit Tract Dis. 2018 Oct;22(4):314-17.全文  摘要

30. Biggar RJ, Chaturvedi AK, Goedert JJ, et al. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst. 2007 Jun 20;99(12):962-72. 摘要

31. Castellsagué X, Muñoz N. Chapter 3: Cofactors in human papillomavirus carcinogenesis: role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr. 2003;(31):20-8. 摘要

32. International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer. 2007 Feb 15;120(4):885-91. 摘要

33. Iversen L, Sivasubramaniam S, Lee AJ, et al. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' oral contraception study. Am J Obstet Gynecol. 2017 Jun;216(6):580.e1-9.全文  摘要

34. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer. 2006 Sep 1;119(5):1108-24.全文  摘要

35. Potischman N, Brinton LA. Nutrition and cervical neoplasia. Cancer Causes Control. 1996 Jan;7(1):113-26. 摘要

36. Yeo AS, Schiff MA, Montoya G, et al. Serum micronutrients and cervical dysplasia in Southwestern American Indian women. Nutr Cancer. 2000;38(2):141-50. 摘要

37. Cao D, Shen K, Li Z, et al. Association between vitamin C Intake and the risk of cervical neoplasia: a meta-analysis. Nutr Cancer. 2016;68(1):48-57. 摘要

38. Hu X, Li S, Zhou L, et al. Effect of vitamin E supplementation on uterine cervical neoplasm: a meta-analysis of case-control studies. PLoS One. 2017 Aug 22;12(8):e0183395.全文  摘要

39. Sikström B, Hellberg D, Nilsson S, et al. Smoking, alcohol, sexual behaviour and drug use in women with cervical human papillomavirus infection. Arch Gynecol Obstet. 1995;256(3):131-7. 摘要

40. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015 Feb 19;372(8):711-23.全文  摘要

41. Centers for Disease Control and Prevention. Supplemental information and guidance for vaccination providers regarding use of 9-valent HPV vaccine. Nov 2016 [internet publication].全文

42. Munoz N, Manalastas R Jr, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. 2009 Jun 6;373(9679):1949-57. 摘要

43. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002 Nov 21;347(21):1645-51. 摘要

44. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004 Nov 13-19;364(9447):1757-65. 摘要

45. Arbyn M, Xu L, Simoens C, et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018 May 9;(5):CD009069.全文  摘要

46. Brisson M, Kim JJ, Canfell K, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020 Feb 22;395(10224):575-90.全文  摘要

47. Marth C, Landoni F, Mahner S, et al. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(suppl_4):iv72-83. 摘要

48. Lei J, Ploner A, Elfström KM, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020 Oct 1;383(14):1340-48.全文  摘要

49. Braaten KP, Laufer MR. Human papillomavirus (HPV), HPV-related disease, and the HPV vaccine. Rev Obstet Gynecol. 2008 Winter;1(1):2-10.全文  摘要

50. UK Health Security Agency. Human papillomavirus (HPV): the green book, chapter 18a. Mar 2022 [internet publication].全文

51. UK Health Security Agency. HPV vaccination guidance for healthcare practitioners (version 6). Apr 2022 [internet publication].全文

52. Saslow D, Andrews KS, Manassaram-Baptiste D, et al. Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation. CA Cancer J Clin. 2020 Jul;70(4):274-80.全文  摘要

53. Centers for Disease Control and Prevention. Child and adolescent immunization schedule. Recommendations for ages 18 years or younger, United States, 2022. Feb 2022 [internet publication].全文

54. Centers for Disease Control and Prevention. Adult immunization schedule. Recommendations for ages 19 years or older, United States, 2022. Feb 2022 [internet publication].全文

55. Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. 11 Jan 2023 [internet publication].全文

56. Meites E, Szilagyi PG, Chesson HW, et al. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019 Aug 16;68(32):698-702.全文  摘要

57. Parazzini F, Negri E, La Vecchia C, et al. Barrier methods of contraception and the risk of cervical neoplasia. Contraception. 1989 Nov;40(5):519-30. 摘要

58. Erbelding EJ, Zenilman JM. Toward better control of sexually transmitted diseases. N Engl J Med. 2005 Feb 17;352(7):720-1. 摘要

59. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007 Nov 24;370(9601):1764-72. 摘要

60. Cortessis VK, Barrett M, Brown Wade N, et al. Intrauterine device use and cervical cancer risk: a systematic review and meta-analysis. Obstet Gynecol. 2017 Dec;130(6):1226-36. 摘要

61. Spotnitz ME, Natarajan K, Ryan PB, et al. Relative risk of cervical neoplasms among copper and levonorgestrel-releasing intrauterine system users. Obstet Gynecol. 2020 Feb;135(2):319-27.全文  摘要

62. Jandorf L, Fatone A, Borker PV, et al. Creating alliances to improve cancer prevention and detection among urban medically underserved minority groups: the East Harlem Partnership for Cancer Awareness. Cancer. 2006 Oct 15;107(8 suppl):2043-51.全文  摘要

63. Siebers AG, Klinkhamer PJ, Grefte JM, et al. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. JAMA. 2009 Oct 28;302(16):1757-64.全文  摘要

64. Koliopoulos G, Nyaga VN, Santesso N, et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev. 2017 Aug 10;(8):CD008587.全文  摘要

65. Ogilvie GS, van Niekerk D, Krajden M, et al. Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial. JAMA. 2018 Jul 3;320(1):43-52.全文  摘要

66. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA. 2002 Apr 24;287(16):2114-9. 摘要

67. Nayar R, Wilbur DC. The Pap test and Bethesda 2014. Cancer Cytopathol. 2015 May;123(5):271-81.全文  摘要

68. Wang J, Andrae B, Sundström K, et al. Risk of invasive cervical cancer after atypical glandular cells in cervical screening: nationwide cohort study. BMJ. 2016 Feb 11;352:i276.全文  摘要

69. National Cancer Institute Workshop. The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses. JAMA. 1989 Aug 18;262(7):931-4. 摘要

70. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: cervical cancer [internet publication].全文

71. Bhatla N, Aoki D, Sharma DN, et al. Cancer of the cervix uteri: 2021 update. Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(suppl 1):28-44.全文  摘要

72. Benedet JL, Bender H, Jones H 3rd, et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynaecol Obstet. 2000 Aug;70(2):209-62. 摘要

73. Choi HJ, Ju W, Myung SK, et al. Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: meta-analysis. Cancer Sci. 2010 Jun;101(6):1471-9.全文  摘要

74. Unger JB, Ivy JJ, Connor P, et al. Detection of recurrent cervical cancer by whole-body FDG PET scan in asymptomatic and symptomatic women. Gynecol Oncol. 2004 Jul;94(1):212-6. 摘要

75. Loft A, Berthelsen AK, Roed H, et al. The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study. Gynecol Oncol. 2007 Jul;106(1):29-34. 摘要

76. Gee MS, Atri M, Bandos AI, et al. Identification of distant metastatic disease in uterine cervical and endometrial cancers with FDG PET/CT: analysis from the ACRIN 6671/GOG 0233 multicenter trial. Radiology. 2018 Apr;287(1):176-84.全文  摘要

77. Schmidt D, Bergeron C, Denton KJ, et al. p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL Papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study. Cancer Cytopathol. 2011 Jun 25;119(3):158-66.全文  摘要

78. US Food and Drug Administration. Recently approved devices: Ventana Medical Systems CINtec PLUS Cytology - P190024. 16 Apr 2020 [internet publication]. 全文

79. Bhatla N, Berek JS, Cuello Fredes M, et al. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2019 Apr;145(1):129-35. 摘要

80. Corrigendum to "Revised FIGO staging for carcinoma of the cervix uteri" [Int J Gynecol Obstet 145(2019) 129-135]. 2019 Nov;147(2):279-80.全文  摘要

81. Union for International Cancer Control Classification. UICC and the TNM classification of malignant tumours. June 2021 [internet publication].全文

82. Bloomfield HE, Olson A, Greer N, et al. Screening pelvic examinations in asymptomatic, average-risk adult women: an evidence report for a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2014 Jul 1;161(1):46-53.全文  摘要

83. Melnikow J, Henderson JT, Burda BU, et al. Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018 Aug 21;320(7):687-705.全文  摘要

84. Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society CA Cancer J Clin. 2020 Sep;70(5):321-46.全文  摘要

85. Committee on Practice Bulletins—Gynecology. Practice bulletin no. 168: cervical cancer screening and prevention. Obstet Gynecol. 2016 Oct;128(4):e111-30. 摘要

86. Sawaya GF, Kulasingam S, Denberg TD, et al. Cervical cancer screening in average-risk women: best practice advice from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2015 Jun 16;162(12):851-9.全文  摘要

87. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012 Apr;137(4):516-42.全文  摘要

88. US Preventive Services Task Force; Curry SJ, Krist AH, Owens DK, et al. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018 Aug 21;320(7):674-86.全文  摘要

89. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention [Internet]. 2nd ed. Geneva: World Health Organization; 2021.全文  摘要

90. World Health Organization. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition: use of mRNA tests for human papillomavirus (‎HPV)‎. Dec 2021 [internet publication].全文

91. Public Health England. Cervical screening: implementation guide for primary HPV screening. 4 Jan 2023 [internet publication].全文

92. Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2020 Apr;24(2):102-31.全文  摘要

93. Bentivegna E, Gouy S, Maulard A, et al. Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review. Lancet Oncol. 2016 Jun;17(6):e240-53. 摘要

94. Kyrgiou M, Athanasiou A, Paraskevaidi M, et al. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. BMJ. 2016 Jul 28;354:i3633.全文  摘要

95. Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000 Apr;18(8):1606-13. 摘要

96. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999 Apr 15;340(15):1137-43.全文  摘要

97. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999 Apr 15;340(15):1154-61.全文  摘要

98. Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001 Sep 8;358(9284):781-6. 摘要

99. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999 May;17(5):1339-48. 摘要

100. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999 Apr 15;340(15):1144-53.全文  摘要

101. Dueñas-González A, Zarbá JJ, Patel F, et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol. 2011 May 1;29(13):1678-85.全文  摘要

102. Landoni F, Maneo A, Cormio G, et al. Class II versus class III radical hysterectomy in stage IB-IIA cervical cancer: a prospective randomized study. Gynecol Oncol. 2001 Jan;80(1):3-12. 摘要

103. Ramirez PT, Frumovitz M, Pareja R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer. N Engl J Med. 2018 Oct 31;379(20):1895-904. 摘要

104. Uppal S, Gehrig PA, Peng K, et al. Recurrence rates in patients with cervical cancer treated with abdominal versus minimally invasive radical hysterectomy: a multi-institutional retrospective review study. J Clin Oncol. 2020 Apr 1;38(10):1030-40. 摘要

105. Melamed A, Margul DJ, Chen L, et al. Survival after minimally invasive radical hysterectomy for early-stage cervical cancer. N Engl J Med. 2018 Oct 31;379(20):1905-14. 摘要

106. Fader AN. Surgery in cervical cancer. N Engl J Med. 2018 Oct 31;379(20):1955-7. 摘要

107. Sedlis A, Bundy BN, Rotman MZ, et al. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group study. Gynecol Oncol. 1999 May;73(2):177-83. 摘要

108. Kim H, Park W, Kim YS, et al. Chemoradiotherapy is not superior to radiotherapy alone after radical surgery for cervical cancer patients with intermediate-risk factor. J Gynecol Oncol. 2020 May;31(3):e35.全文  摘要

109. ClinicalTrials.gov (US). Radiation therapy with or without chemotherapy in patients with stage I-IIA cervical cancer who previously underwent surgery (ClinicalTrials.gov Identifier: NCT01101451). 24 May 2022 [internet publication]​.全文

110. Gien LT, Covens A. Fertility-sparing options for early stage cervical cancer. Gynecol Oncol. 2010 May;117(2):350-7. 摘要

111. Bentivegna E, Maulard A, Pautier P, et al. Fertility results and pregnancy outcomes after conservative treatment of cervical cancer: a systematic review of the literature. Fertil Steril. 2016 Oct;106(5):1195-211;e5.全文  摘要

112. Green J, Kirwan J, Tierney J, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD002225.全文  摘要

113. Rose PG, Ali S, Watkins E, et al. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007 Jul 1;25(19):2804-10.全文  摘要

114. Pötter R, Tanderup K, Schmid MP, et al. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Lancet Oncol. 2021 Apr;22(4):538-47. 摘要

115. Sturdza AE, Knoth J. Image-guided brachytherapy in cervical cancer including fractionation. Int J Gynecol Cancer. 2022 Mar;32(3):273-80.全文  摘要

116. Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol. 2004 Mar 1;22(5):872-80.全文  摘要

117. Lanciano RM, Won M, Coia LR, et al. Pretreatment and treatment factors associated with improved outcome in squamous cell carcinoma of the uterine cervix: a final report of the 1973 and 1978 patterns of care studies. Int J Radiat Oncol Biol Phys. 1991 Apr;20(4):667-76. 摘要

118. Hanks GE, Herring DF, Kramer S. Patterns of care outcome studies: results of the national practice in cancer of the cervix. Cancer. 1983 Mar 1;51(5):959-67.全文  摘要

119. Coia L, Won M, Lanciano R, et al. The patterns of care outcome study for cancer of the uterine cervix: results of the second national practice survey. Cancer. 1990 Dec 15;66(12):2451-6. 摘要

120. Montana GS, Martz KL, Hanks GE. Patterns and sites of failure in cervix cancer treated in the U.S.A. in 1978. Int J Radiat Oncol Biol Phys. 1991 Jan;20(1):87-93. 摘要

121. Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med. 2021 Nov 11;385(20):1856-67.全文  摘要

122. Höckel M, Dornhöfer N. Pelvic exenteration for gynaecological tumours: achievements and unanswered questions. Lancet Oncol. 2006 Oct;7(10):837-47. 摘要

123. Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24(suppl 6):vi160-70.全文  摘要

124. Amant F, Berveiller P, Boere IA, et al. Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. Ann Oncol. 2019 Oct 1;30(10):1601-12.全文  摘要

125. Zagouri F, Sergentanis TN, Chrysikos D, et al. Platinum derivatives during pregnancy in cervical cancer: a systematic review and meta-analysis. Obstet Gynecol. 2013 Feb;121(2 Pt 1):337-43. 摘要

126. Janku F, Wheler JJ, Westin SN, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012 Mar 10;30(8):777-82.全文  摘要

127. Juric D, Rodon J, Tabernero J, et al. Phosphatidylinositol 3-kinase α-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study. J Clin Oncol. 2018 May 1;36(13):1291-9.全文  摘要

128. Symonds RP, Gourley C, Davidson S, et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol. 2015 Nov;16(15):1515-24.全文  摘要

129. Wallecha A, French C, Petit R, et al. Lm-LLO-based immunotherapies and HPV-associated disease. J Oncol. 2012;2012:542851.全文  摘要

130. Basu P, Mehta AO, Jain MM, et al. ADXS11-001 immunotherapy targeting HPV-E7: final results from a phase 2 study in Indian women with recurrent cervical cancer. J Clin Oncol. 2014;32:5(suppl);5610.

131. Huh WK, Dizon DS, Powell MA, et al. ADXS11-001 immunotherapy in squamous or non-squamous persistent/recurrent metastatic cervical cancer: results from stage I of the phase II GOG/NRG0265 study. J Clin Oncol. 2016;34:S5516.全文

132. Basu P, Mehta A, Jain M, et al. A randomized phase 2 study of ADXS11-001 Listeria monocytogenes-listeriolysin O immunotherapy with or without cisplatin in treatment of advanced cervical cancer. Int J Gynecol Cancer. 2018 May;28(4):764-72.全文  摘要

133. ClinicalTrials.gov. A phase II study of balstilimab independently or in combination with zalifrelimab in advanced cervical cancer​ (ClinicalTrials.gov Identifier NCT05033132). August 2022 [internet publication].全文

134. ClinicalTrials.gov. A study of camrelizumab combined with concurrent chemoradiation in patients with cervical cancer (ClinicalTrials.gov Identifier NCT04974827). August 2021 [internet publication].全文

135. ClinicalTrials.gov. Camrelizumab combined with radiotherapy and chemotherapy for the treatment of recurrent or metastatic cervical cancer (ClinicalTrials.gov Identifier NCT04884906). May 2021 [internet publication].全文  摘要

136. ClinicalTrials.gov. Nivolumab-ipilimumab and chemoradiation for cervical cancer (ClinicalTrials.gov Identifier NCT05492123). Dec 2022 [internet publication].​​全文

137. Tewari KS, Monk BJ, Vergote I, et al. Survival with cemiplimab in recurrent cervical cancer. N Engl J Med. 2022 Feb 10;386(6):544-55.全文  摘要

138. Keam SJ. Cadonilimab: First Approval. Drugs. 2022 Aug;82(12):1333-39. 摘要

139. Trimble CL, Morrow MP, Kraynyak KA, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet. 2015 Nov 21;386(10008):2078-88.全文  摘要

140. Stevanović S, Draper LM, Langhan MM, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 2015 May 10;33(14):1543-50.全文  摘要

141. Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer. 2003 Nov;39(17):2470-86. 摘要

142. Eddy GL, Bundy BN, Creasman WT, et al. Treatment of ("bulky") stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group. Gynecol Oncol. 2007 Aug;106(2):362-9. 摘要

143. Kim HS, Sardi JE, Katsumata N, et al. Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer: an international collaborative meta-analysis. Eur J Surg Oncol. 2013 Feb;39(2):115-24. 摘要

144. Katsumata N, Yoshikawa H, Kobayashi H, et al. Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102). Br J Cancer. 2013 May 28;108(10):1957-63.全文  摘要

145. Gupta S, Maheshwari A, Parab P, et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. J Clin Oncol. 2018 Jun 1;36(16):1548-55.全文  摘要

146. Rydzewska L, Tierney J, Vale CL, et al. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev. 2012 Dec 12;(12):CD007406.全文  摘要

147. Zou W, Han Y, Zhang Y, et al. Neoadjuvant chemotherapy plus surgery versus concurrent chemoradiotherapy in stage IB2-IIB cervical cancer: a systematic review and meta-analysis. PLoS One. 2019;14(11):e0225264.全文  摘要

148. Marchetti C, Fagotti A, Tombolini V, et al. Survival and toxicity in neoadjuvant chemotherapy plus surgery versus definitive chemoradiotherapy for cervical cancer: a systematic review and meta-analysis. Cancer Treat Rev. 2020 Feb;83:101945. 摘要

149. Kietpeerakool C, Aue-Aungkul A, Galaal K, et al. Nerve-sparing radical hysterectomy compared to standard radical hysterectomy for women with early stage cervical cancer (stage Ia2 to IIa). Cochrane Database Syst Rev. 2019 Feb 12;(2):CD012828.全文  摘要

150. Friedlander M, Grogan M; US Preventive Services Task Force. Guidelines for the treatment of recurrent and metastatic cervical cancer. Oncologist. 2002;7(4):342-7.全文  摘要

151. Elit L, Fyles AW, Oliver TK, et al. Follow-up for women after treatment for cervical cancer. Curr Oncol. 2010 Jun;17(3):65-9.全文  摘要

152. American Cancer Society. Survival rates for cervical cancer. 2 Feb 2021 [internet publication].全文

153. Suk R, Mahale P, Sonawane K, et al. Trends in risks for second primary cancers associated with index human papillomavirus-associated cancers. JAMA Netw Open. 2018 Sep 7;1(5):e181999.全文  摘要

154. Bergmark K, Avall-Lundqvist E, Dickman PW, et al. Vaginal changes and sexuality in women with a history of cervical cancer. N Engl J Med. 1999 May 6;340(18):1383-9.全文  摘要

155. Kirchheiner K, Nout RA, Lindegaard JC, et al. Dose-effect relationship and risk factors for vaginal stenosis after definitive radio(chemo)therapy with image-guided brachytherapy for locally advanced cervical cancer in the EMBRACE study. Radiother Oncol. 2016 Jan;118(1):160-6. 摘要

156. Penson RT, Wenzel LB, Vergote I, et al. Quality of life considerations in gynecologic cancer: FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006 Nov;95(suppl 1):S247-57. 摘要

157. Fokdal L, Pötter R, Kirchheiner K, et al. Physician assessed and patient reported urinary morbidity after radio-chemotherapy and image guided adaptive brachytherapy for locally advanced cervical cancer. Radiother Oncol. 2018 Jun;127(3):423-30. 摘要

158. Jensen NBK, Pötter R, Kirchheiner K, et al. Bowel morbidity following radiochemotherapy and image-guided adaptive brachytherapy for cervical cancer: Physician- and patient reported outcome from the EMBRACE study. Radiother Oncol. 2018 Jun;127(3):431-9. 摘要